SK Bioscience's SKYCellflu approved by Chilean health authority

Q: How long will it take to read this news story?

The story "SK Bioscience&#039;s SKYCellflu approved by Chilean health authority" has 167 words across 12 sentences, which will take approximately 1 - 2 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "SK Bioscience&#039;s SKYCellflu approved by Chilean health authority" was covered 1 months ago by Korea Economic Daily, a news publisher based in South Korea.

Q: How trustworthy is 'Korea Economic Daily' news outlet?

Korea Economic Daily is a fully independent (privately-owned) news outlet established in 1964 that covers mostly economy news. The outlet is headquartered in South Korea and publishes an average of 0 news stories per day. It's most recent story was published 1 days ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #5072107</li><li>URL: https://beamstart.com/news/sk-biosciences-skycellflu-approved-by-167531855625</li></ul>

Korea Economic Daily Logo Korea Economic Daily 1 mo ago

SK Bioscience's SKYCellflu approved by Chilean health authority - Korea Economic Daily

Quick Summary:

SK Bioscience Co., a bio and pharmaceutical affiliate of South Korea's SK Group, announced on Thursday that its world-first cell culture-based quadrivalent influenza vaccine SKYCellflu has received approval from the Instituto de Salud Publica de Chile (Chilean Institute of Public Health).

SK Bioscience plans to expand its global flu vaccine market into Central and South America with approval in Chile.

SKYCellflu has a shorter manufacturing period than traditional egg-based vaccines and has shown acceptable levels of immunogenicity and safety in clinical trials with over 1,500 adults and 453 children.